estra-1,3,5(10),7-tetraene-3,17α-diol | 651-55-8

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: estra-1,3,5(10),7-tetraene-3,17α-diol
• 英文别名: 17α-dihydroequilin；α-Dihydroequilin；17alpha-dihydroequilin；Alpha-Dihydroequilin；dihydroequilin；Estra-1,3,5(10),7-tetraene-3,17-diol, (17alpha)-；13-methyl-6,9,11,12,14,15,16,17-octahydrocyclopenta[a]phenanthrene-3,17-diol
• CAS: 651-55-8；3563-27-7；23392-56-5；56143-08-9；109715-10-8
• 化学式: C₁₈H₂₂O₂
• 分子量: 270.371
• InChiKey: NLLMJANWPUQQTA-UHFFFAOYSA-N

物化性质

• 熔点：
  174.5-174.6°
• 比旋光度：
  D20 +220° (dioxane)
• 沸点：
  457.8±45.0 °C(Predicted)
• 密度：
  1.22±0.1 g/cm3(Predicted)
• 溶解度：
  丙酮（微溶）、DMSO（微溶）、乙醇（微溶）、甲醇（微溶）
• 保留指数：
  2751.6;2772.5;2772.7

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  20
• 可旋转键数：
  0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  40.5
• 氢给体数：
  2
• 氢受体数：
  2

文献信息

• [EN] SUBSTITUTED PIPERAZINES AS CB1 ANTAGONISTS<br/>[FR] PIPÉRAZINES SUBSTITUÉES EN TANT QU'ANTAGONISTES DE CB1
  申请人：SCHERING CORP

  公开号：WO2009005645A1

  公开（公告）日：2009-01-08

  Compounds of Formula (I) or pharmaceutically acceptable salts, solvates, or esters thereof, are useful in treating diseases or conditions mediated by CB1 receptors, such as metabolic syndrome and obesity, neuroinflammatory disorders, cognitive disorders and psychosis, addiction (e.g., smoking cessation), gastrointestinal disorders, and cardiovascular conditions.

  化合物式(I)或其药用可接受的盐、溶剂合物或酯，可用于治疗由CB1受体介导的疾病或症状，如代谢综合征和肥胖症、神经炎症性疾病、认知障碍和精神病、成瘾（例如戒烟）、胃肠道疾病和心血管疾病。
• Multi-functional ionic liquid compositions for overcoming polymorphism and imparting improved properties for active pharmaceutical, biological, nutritional, and energetic ingredients
  申请人：Rogers D. Robin

  公开号：US20070093462A1

  公开（公告）日：2007-04-26

  Disclosed are ionic liquids and methods of preparing ionic liquid compositions of active pharmaceutical, biological, nutritional, and energetic ingredients. Also disclosed are methods of using the compositions described herein to overcome polymorphism, overcome solubility and delivery problems, to control release rates, add functionality, enhance efficacy (synergy), and improve ease of use and manufacture.

  揭示了离子液体及制备活性药物、生物、营养和能量成分的离子液体组合物的方法。还揭示了利用本文描述的组合物的方法，以克服多型性、克服溶解度和输送问题、控制释放速率、增加功能性、增强功效（协同作用）以及改善易用性和制造工艺。
• [EN] DUAL FUNCTIONING IONIC LIQUIDS AND SALTS THEREOF<br/>[FR] LIQUIDES IONIQUES À DOUBLE FONCTION ET SELS DE CEUX-CI
  申请人：UNIV ALABAMA

  公开号：WO2010078300A1

  公开（公告）日：2010-07-08

  Disclosed herein are ionic liquid compositions comprising active pharmaceutical, biological, and nutritional compounds, and methods of use. Further disclosed are compositions of matter including liquid ion pairs alone or in solution and their use; compositions of ionic liquids that are 'solvated,' for example, 'hydrated' and their uses.

  本文揭示了包括活性药物、生物学和营养化合物的离子液体组合物，以及其使用方法。进一步揭示了包括液态离子对的物质组合物，单独或溶解后使用；以及离子液体的“溶剂化”组合物，例如“水合”的组合物及其用途。
• PROCESS FOR SELECTIVE SULFATION OF AROMATIC HYDROXYL GROUPS
  申请人：MEGATI Sreenivasulu

  公开号：US20080194533A1

  公开（公告）日：2008-08-14

  The present invention relates to processes for selective sulfation of an aromatic hydroxyl group over an aliphatic hydroxyl group where both are present in the same molecule. This invention also relates to processes for selective sulfation of the aromatic hydroxyl group of equilin, equilenin, estradiol, estra(1,3,5-triene)-3,16,17-triol, dihydroequilenin or dihydroequilin. This invention further relates to alkali metal salts of dihydroequilenin sulfates, dihydroequilin sulfates, estradiol sulfates, and estriol sulfates, processes for making thereof, stable compositions comprising thereof, and the use thereof.

  本发明涉及一种对同一分子中同时存在的芳香羟基和脂肪族羟基进行选择性磺酸化的方法。该发明还涉及对equilin、equilenin、雌二醇、雌三烯-3,16,17-三醇、二氢equilenin或二氢equilin的芳香羟基进行选择性磺酸化的方法。此外，该发明还涉及二氢equilenin磺酸盐、二氢equilin磺酸盐、雌二醇磺酸盐和雌三醇磺酸盐的碱金属盐、制备方法、稳定组合物及其用途。
• USE OF ISOINDOLES FOR THE TREATMENT OF NEUROBEHAVIORAL DISORDERS
  申请人：Kovacs Bruce

  公开号：US20090318520A1

  公开（公告）日：2009-12-24

  The present invention generally relates to the use of drugs for the treatment of neurobehavioral disorders or symptoms of a neurobehavioral disorder associated with dysfunction of the trimonoamine modulating system (TMMS). More specifically, the invention describes methods for the treatment of a neurobehavioral disorder and/or treatment or prevention of symptoms of a neurobehavioral disorder by administering suitable Isoindole derivatives alone or in combination with other agents so as to provide relatively equal inhibitory effect on serotonin, dopamine and norepinephrine transporters.

  本发明一般涉及使用药物治疗与三单胺调节系统（TMMS）功能障碍相关的神经行为障碍或症状。更具体地，该发明描述了通过单独或与其他药物联合给予适当的异吲哚衍生物以在血清素、多巴胺和去甲肾上腺素转运体上提供相对平等的抑制作用，用于治疗神经行为障碍和/或治疗或预防神经行为障碍症状的方法。

表征谱图